☆ 4.6 Article

Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms

DRUGS (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Sofia Ramiro et al.

Summary: The ASAS-EULAR recommendations provide updated guidance on the management of axial spondyloarthritis, including treatment targets, non-pharmacological interventions, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the first-line pharmacological treatment. For patients with comorbidities, the use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is recommended. The recommendations also cover the management of extramusculoskeletal manifestations, tapering of bDMARDs, and surgical interventions.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Rheumatology

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Casper Webers et al.

Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Rheumatology

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Augusta Ortolan et al.

Summary: This study updated the evidence of non-biological treatments for axSpA, providing a basis for the 2022 ASAS-EULAR recommendations. The results showed that education, exercise, and NSAIDs were efficacious in axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Rheumatology

Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Ennio Lubrano et al.

Summary: Objective. The objective of this study was to identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. Methods. This systematic review updated the treatment recommendations for axial PsA. Results. The literature review revealed that new biologic and targeted synthetic disease-modifying antirheumatic drug classes could be considered for the treatment of axial PsA. Conclusion. Further studies are needed for a better understanding of the treatment of axial PsA.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde et al.

Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Jeffrey R. Curtis et al.

Summary: This study evaluated malignancies and their associations with baseline risk factors and cardiovascular risk scores in patients with rheumatoid arthritis (RA) treated with tofacitinib and tumour necrosis factor inhibitors (TNFi). The results showed that the risk of malignancies was increased with tofacitinib compared to TNFi, and the highest incidence was observed in patients with a history of atherosclerotic cardiovascular disease (HxASCVD) or increasing cardiovascular risk.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Rheumatology

Choose wisely: imaging for diagnosis of axial spondyloarthritis

Torsten Diekhoff et al.

Summary: The study found that compared to CT and MRI, X-ray had lower sensitivity and inferior specificity for axSpA. However, CT showed the best inter-rater reliability, highlighting the importance of structural lesions for the differential diagnosis in axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group

Xenofon Baraliakos et al.

Summary: This study updated and validated the definitions of spinal MRI lesions associated with axial spondyloarthritis (axSpA), focusing on inflammatory and structural lesions in terms of localization, extension, and extent, with new classifications based on lesion maturity. The reliability assessment confirmed VC fat lesion and VC monomorphic inflammatory lesion as the most reliably assessed lesions.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study

Fabian Proft et al.

Summary: A dermatologist-centred screening tool followed by a structured rheumatological examination, including MRI, can be effective in recognizing psoriatic arthritis with axial involvement.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Atul Deodhar et al.

LANCET (2022)

Add to Collection

Article Rheumatology

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Laura C. Coates et al.

Summary: This article presents evidence-based treatment recommendations for Psoriatic Arthritis (PsA) medication selection, covering various clinical domains, related conditions and comorbidities. It provides important guidance and support for clinicians and individuals with PsA.

NATURE REVIEWS RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Dafna D. Gladman et al.

Summary: This study aims to evaluate the efficacy of guselkumab in reducing axial symptoms and inflammation in patients with active PsA.

TRIALS (2022)

Add to Collection

Article Rheumatology

A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis

Peter C. Taylor et al.

Summary: The study found no clinical benefit with apremilast treatment in patients with active ankylosing spondylitis. Results from the placebo-controlled study did not meet expectations in terms of ASAS20 response. The most frequently reported adverse events included diarrhea, nasopharyngitis, and nausea.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial

Fabian Proft et al.

Summary: Psoriatic arthritis (PsA) is an inflammatory disease characterized by synovitis, enthesitis, dactylitis and axial involvement. The efficacy of tofacitinib in reducing inflammation in axial PsA patients will be evaluated in a randomized, double-blind, placebo-controlled clinical trial involving 80 participants with active disease.

BMJ OPEN (2021)

Add to Collection

Article Rheumatology

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Atul Deodhar et al.

Summary: Tofacitinib demonstrated significantly greater efficacy compared to placebo in treating active ankylosing spondylitis in adults, with good safety profile and no new safety risks identified.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Clinical features of psoriatic arthritis

Mitsumasa Kishimoto et al.

Summary: Psoriatic arthritis (PsA) is a joint disease associated with decreased quality of life, and early diagnosis and treatment are crucial for disease control. Understanding both the peripheral and axial manifestations of PsA, in addition to skin and nail lesions, is important for swift diagnosis.

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

Philip J Mease et al.

Lancet Rheumatology (2021)

Add to Collection

Article Rheumatology

Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort

Joy Feld et al.

Summary: This study aimed to assess the presence and radiographic progression of axial psoriatic arthritis, as well as to identify risk factors associated with progression. Axial disease was detected in over 45% of patients, with 52% progressing to the criteria of ankylosing spondylitis within 5.5 years. Younger age, less degenerative disc disease, and more severe psoriasis were associated with progression in this study.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

Add to Collection

Article Rheumatology

Axial involvement in psoriatic arthritis: An update for rheumatologists

Denis Poddubnyy et al.

Summary: Psoriatic arthritis (PsA) is a chronic, inflammatory musculoskeletal disease with heterogeneous characteristics, and axial involvement can lead to complications in management and treatment decisions. The lack of agreed-upon classification and diagnostic criteria for axial PsA complicates the approach to this subset of patients.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

Add to Collection

Article Rheumatology

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Denis Poddubnyy et al.

Summary: The AXIS study aims to systematically evaluate clinical and imaging manifestations indicative of axial involvement in patients with PsA, in order to develop classification criteria and a unified nomenclature for defining a homogeneous subgroup of patients for research.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)

Add to Collection

Article Rheumatology

Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years

Xenofon Baraliakos et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Editorial Material Rheumatology

Axial disease in psoriatic arthritis

Philip S. Helliwell

RHEUMATOLOGY (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC)

Carsten Oliver Schmidt et al.

BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ (2020)

Add to Collection

Article Rheumatology

Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis

Denis Poddubnyy et al.

RHEUMATOLOGY (2020)

Add to Collection

Review Rheumatology

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

Laure Gossec et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Article Rheumatology

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

Philip S. Helliwell et al.

RMD OPEN (2020)

Add to Collection

Article Rheumatology

What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis

Xenofon Baraliakos et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Review Rheumatology

Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?

Vinod Chandran

CURRENT OPINION IN RHEUMATOLOGY (2019)

Add to Collection

Article Rheumatology

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group

Walter P. Maksymowych et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Review Rheumatology

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis

Joachim Sieper et al.

NATURE REVIEWS RHEUMATOLOGY (2019)

Add to Collection

Article Rheumatology

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Atul Deodhar et al.

ARTHRITIS & RHEUMATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Desiree van der Heijde et al.

LANCET (2019)

Add to Collection

Article Rheumatology

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Philip J. Mease et al.

JOURNAL OF RHEUMATOLOGY (2018)

Add to Collection

Review Rheumatology

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison

Joy Feld et al.

NATURE REVIEWS RHEUMATOLOGY (2018)

Add to Collection

Article Rheumatology

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

Add to Collection

Article Rheumatology

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care

Denis Poddubnyy et al.

RMD OPEN (2018)

Add to Collection

Article Rheumatology

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Josef S. Smolen et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

Add to Collection

Article Rheumatology

Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis

Deepak R. Jadon et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Add to Collection

Review Rheumatology

What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?

Lihi Eder et al.

CURRENT OPINION IN RHEUMATOLOGY (2015)

Add to Collection

Review Biochemistry & Molecular Biology

The critical role of interleukin-23 in spondyloarthropathy

Jonathan P. Sherlock et al.

MOLECULAR IMMUNOLOGY (2014)

Add to Collection

Article Rheumatology

Magnetic Resonance Imaging Assessment of Axial Psoriatic Arthritis: Extent of Disease Relates to HLA-B27

Concepcion Castillo-Gallego et al.

ARTHRITIS AND RHEUMATISM (2013)

Add to Collection

Article Rheumatology

The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis

Ilaria Tinazzi et al.

RHEUMATOLOGY (2012)

Add to Collection

Article Rheumatology

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

I-H Song et al.

ANNALS OF THE RHEUMATIC DISEASES (2011)

Add to Collection

Meeting Abstract Rheumatology

Polymorphism 4g/5g of the PAI-1 Gene and Atherosclerosis Detection Using Carotid Ultrasound in Patients with Systemic Lupus Erythematosus

B. Cepeda et al.

JOURNAL OF RHEUMATOLOGY (2011)

Add to Collection

Article Rheumatology

Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis

Vinod Chandran et al.

JOURNAL OF RHEUMATOLOGY (2010)

Add to Collection

Article Rheumatology

Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)

D. D. Gladman et al.

ANNALS OF THE RHEUMATIC DISEASES (2009)

Add to Collection

Article Rheumatology

Axial Psoriatic Arthritis: Update on a Longterm Prospective Study

Vinod Chandran et al.

JOURNAL OF RHEUMATOLOGY (2009)

Add to Collection

Article Rheumatology

Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis

L Williamson et al.

RHEUMATOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.